Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR
This clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Conventional radiotherapy use
| Condition(s) | Ewing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Conventional radiotherapy uses minimal imaging support to determine the positioning of radiotherapy. Hypofractionated radiotherapy delivers higher doses of radiotherapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Dose-escalated radiotherapy uses doses that are higher than those used in conventional radiotherapy. Larger tumor sizes and other tumor-specific characteristics have been shown to be related to poorer outcomes. In addition, after dose-escalated radiot |
| Who can participate | Inclusion Criteria: * Histological confirmation of Ewing sarcoma, including both skeletal and extra-skeletal primary tumors. Patients with "Ewing-like" sarcoma may be eligible if patients are planned to be treated per Ewing treatment paradigms, as defined in this clinical trial * Patients of age ≥ 2 years are eligible for the study * Lansky or Karnofsky performance status ≥ 70 * Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance * Willing to provide blood samples for correlative research purposes * Willing to provide biopsy sample to run Mayo Complete Solid Tumor Panel if tumor size is \>= 8 cm Exclusion Criteria: * Prior chemotherapy or radiotherapy that, in the opinion of the treating medical oncologist or radiation oncologist, is c |
| Ages | 2 Years |
| Sex | All |
| Lead sponsor | Mayo Clinic |
| Locations | Phoenix, Arizona, United States; Rochester, Minnesota, United States |
| Start date | 2025-11-24 |
| NCT ID | NCT07188532 |
| Official listing | https://clinicaltrials.gov/study/NCT07188532 |